Increased transglutaminase 2 and GLUT-1 expression in breast tumors not susceptible to chemoprevention with antioxidants

Tumori

Volumn 95, Issue 2, 2009, Pages 227-232

  Martins, Filipe C ^a,b   Teixeira, Filipa ^b   Reis, Ines ^b   Geraldes, Nuno ^b   Cabrita, AM Silverio ^b   Dias, Margarida F ^a,b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Antioxidants; Breast cancer; Chemoprevention; Prognostic markers

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CLAUDIN 1; DIMETHYLBENZ[A]ANTHRACENE; GLUCOSE TRANSPORTER 1; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SELENIUM; TRACE ELEMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST LESION; BREAST TUMOR; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG SENSITIVITY; EXPERIMENTAL STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; RAT; WISTAR RAT;

EID: 67649107776     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160909500215     Document Type: Article

References (86)

1. Dias M, Cabrita S, Sousa E, Franca B, Patricio J, Oliveira C: Benign and malignant mammary tumors induced by DM-BA in female Wistar rats. Eur J Gynaec Oncol, 20: 285-288, 1999.
2. Dias MF, Sousa E, Cabrita S, Patricio J, Oliveira CF: Chemoprevention of DMBA-induced mammary tumors in rats by combined regimen of alpha-tocopherol, selenium and ascorbic acid. Breast J, 6: 14-19, 2000.
3. Middleton PJ: The histogenesis of mammary tumors induced in the rat by chemical carcinogens. Br ] Cancer, 19: 830-839, 1965.
4. Geyer RP, Bleish VR, Bryant JE, Robbins AN, Saslaw 1M, Stare FJ: Tumor production in rats injected intravenously with oil emulsions containing 9,10-dimethyl-l, 2-benzan-thracene. Cancer Res, 11: 474-478, 1951.
5. Russo J, Russo IH: Susceptibility of the mammary gland to carcinogenesis. Am J Pathol, 100: 497-512, 1980.
6. Medina D: The mammary gland: a unique organ to the study of development and tumorigenesis. J Mammary Gland Biol Neoplasia, 1: 5-19, 1996.
7. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ: Comparative study of human and rat tumorigenesis. Lab Invest, 62: 244-278, 1990.
8. Issacs JT: Genetic control of resistance to chemically-induced mammary adenocarcinogenesis in the rat. Cancer Res, 46: 3958-3963, 1986.
9. Russo J, Russo IH: Biological and molecular bases of mammary carcinogenesis. Lab Invest, 57: 112-137, 1987.
10. Kallman RF: Rodent tumor models in experimental cancer therapy, 12th ed, Pergamon, New York, 1987.
11. Hsu LC, Kennan WS, Shepel LA, lacob HI, Szpirer C, Szpir-er J, Lander ES, Gould MN: Genetic identification of Mcs-1, a rat mammary carcinoma suppressor gene. Cancer Res, 54: 2765-2770, 1994.
12. Welsh CW: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas. A review and tribute to Charles Brenton Huggins. Cancer Res, 45: 3415-3443, 1985.
13. Russo I, Tay LK, Russo IH: Differentiation of mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat, 2:5-73, 1982.
14. Russo J, Saby I, Isenberg WM, Russo IH: Pathogenesis of mammary carcinomas induced in rats by 7,12-dimethyl-benz[a]anthracene. J Natl Cancer Inst, 59: 435-445, 1977.
15. Russo IH, Russo J: Developmental stage of the rat mammary gland as a determinant of its susceptibility to 7,12-di-methylbenz[a]anthracene. J Natl Cancer Inst, 61: 1439-1449, 1978.
16. Haslam SZ: The effect of age on the histopathogenesis of 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the Lewis rat. Inst J Cancer, 26: 349-356, 1980.
17. Nagasawa H, Yanai R: Frequency of mammary cell division in relation to age: its significance in the induction of mammary tumors by carcinogen in rats. J Natl Cancer Inst, 52: 609-610, 1974.
18. Dao TL: Mammary cancer induction by 7,12-dimethyl-benz[a]anthracene. Relation to age. Science, 165: 810-811, 1969.
19. Thordarson G, Jin E, Guzman RC, Swanson SM, Nandi S, Talamantes F: Refractoriness to mammary tumorigenesis in parous rats: is it caused by persistent changes in the hormonal environment or permanent biochemical alterations in the mammary epithelia? Carcinogenesis, 16: 2847-2853, 1995.
20. Russo J, Russo IH, Ireland M, Saby J: Increased resistance of multiparous rat mammary gland to neoplastic transformation by DMBA. Proc Am Assoc Cancer Res, 18: 149, 1977.
21. Moon RC: Relationship between previous reproductive history and chemical mammary cancer in rats. Inst J Cancer, 4: 312-317, 1969.
22. Sinha DK, Pazik JE, Dao TL: Prevention of mammary car-cinogenesis in rats by pregnancy: effect of full-term and interrupted pregnancy. Br J Cancer, 57: 390-397, 1988.
23. Sylvester PW, Aylsworth CF, Van Vugt DA, Meites J: Effects of alterations in early hormonal dependency of carcinogen-induced mammary tumors in rats. Cancer Res, 43: 5342-5346, 1983.
24. Ciocca DR, Parente A, Russo J: Endocrinologic milieu and susceptibility of the rat mammary gland to carcinogenesis. Am J Pathol, 109: 47-56, 1982.
25. Huggins C, Grand LC, Brillantes FP: Mammary cancer induced by single feeding of polynuclear hydrocarbons and its suppression. Nature, 189: 204-207, 1961.
26. Gullino PM, Pettigrevy HM, Grantham FH: N-nitro-somethylurea as mammary carcinogen in rats. J Natl Cancer Inst, 54: 401-414, 1975.
27. Janss DH, Moon RC, Irving CC: The binding of 7,12-di-methylbenz [a] anthracene to mammary parenchyma DNA and protein in vivo. Cancer Res, 32: 254-258, 1972.
28. Ip C, Vadhanavikit S, Ganther H: Cancer chemoprevention by aliphatic selenocyanates: effect of chain length on inhibition of mammary tumors and DMBA adducts. Carcinogenesis, 16: 35-38, 1995.
29. Noguchi M, Minami M, Yagasaki R, Kinoshita K, Earashi M, Kitagawa H, Taniya T, Miyasaki I: Chemoprevention of DM-BA-induced mammary carcinogenesis in rats by low dose EPA and DHA. Br J Cancer, 75: 348-353, 1997.
30. Ip C, Lisk DJ, Thompson HJ: Selenium-enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Carcinogenesis, 17:1979-1982, 1996.
31. El-Sohemy A, Bruce WR, Archer MC: Inhibition of rat mammary tumorigenesis by dietary cholesterol. Carcinogenesis, 17: 159-162, 1996.
32. Baum A, Mevissen M, Kamino K, Mohr U, Loscher W: A histopathological study on alterations in DMBA-induced mammary carcinogenesis in rats with 50 Hz, 100 uT magnetic field exposure. Carcinogenesis, 16(1): 119-126, 1995.
33. Ip C, Lisk DJ: Efficacy of cancer prevention by high-selenium garlic is primarily dependent on the actin of selenium. Carcinogenesis, 16: 2649-2652, 1995.
34. Wu L, Mcgarry L, Lanfear J, Harrison PR: Altered selenium-binding protein levels associated with selenium resistance. Carcinogenesis, 16(11): 2819-2824, 1995.
35. Garland M, Morris JS, Stampfer MJ: Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst, 87(7): 497-505, 1995.
36. Harman D: Dimethylbenz[a]anthracene induced cancer: inhibitory effect of dietary vitamin E. Clin Res, 17:125-129, 1969.
37. Ip C, Lisk DJ: Characterization of tissue selenium profiles and anticarcinogenic responses in rats fed natural sources of selenium-rich products. Carcinogenesis, 15(4): 573-576, 1994.
38. Thompson HJ, Wilson A, Lu J, Singh M, Jiang C, Upadhyaya P, el-Bayoumy K, Ip C: Comparison of the effects of an organic and inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis, 15: 183-186, 1994.
39. Ip C, Ip MM: Chemoprevention of mammary tumorigenesis by a combined regimen of selenium and vitamin A. Carcinogenesis, 2: 915-918, 1981.
40. Medina D, Shepherd F: Selenium-mediated inhibition of 7,12-dimethylbenz[a]anthracene-induced mouse mammary tumorigenesis. Carcinogenesis, 2: 451-455, 1981.
41. Ip C, Ganther HE: Activity of methylated forms of selenium in cancer prevention. Cancer Res, 50: 1206-1211, 1990.
42. Ip C: Prophylaxis of mammary neoplasia by selenium sup-plementation in the initiation and promotion phase of chemical carcinogenesis. Cancer Res, 41: 4386-4390, 1981.
43. Medina D, Shepherd F: Selenium-mediated inhibition of mouse mammary tumorigenesis. Cancer Lett, 8: 241-245, 1980.
44. Liu J, Gilbert K, Parker HM, Haschek NM, Milner JA: Inhibition of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and DNA adducts by dietary selenite. Cancer Res, 51: 4613-4617, 1991.
45. El-Bayoumy K: Evaluation of chemopreventive agents against breast cancer and proposed strategies for future clinical intervention trials. Carcinogenesis, 15: 2395-2429, 1994.
46. Novotny JA, Milner JA: Impact of ascorbic acid on selenium-induced growth inhibition of canine mammary tumor cells in vitro. J Nutr Biochem, 4: 341-345, 1993.
47. Hovarth P, Ip C: Synergistic effect of vitamin E and selenium in chemoprevention of mammary carcinogenesis in rats. Cancer Res, 43: 5335-5341, 1983.
48. Ip C, El-Bayoumy K, Upadhyaya P, Ganther H, Vadhanavikit S, Thompson H: Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention. Carcinogenesis, 15:187-192,1994.
49. Takada H, Hirooka T, Hatano T, Hamada Y, Yamamoto M: Inhibition of 7,12-dimethylbenz[a]anthracene-induced lipid peroxidation and mammary tumor development in rats by vitamin E in conjunction with selenium. Nutr Cancer, 17: 115-122, 1992.
50. Ip C: Dietary vitamin E intake and mammary carcinogenesis in rats. Carcinogenesis, 3: 1453-1456,1982.
51. Li J, Shi M, Cao Y, Yuan W, Pang T, Li B, Sun Z, Chen L, Zhao RC: Knockdown of hypoxia-inducible factor-lalpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun, 342:1341-1351, 2006.
52. Stackhouse B L, Williams H, Berry P, Russel G, Thompson P, Winter JL, Kute T: Measurement of Glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer. Breast Cancer Res Treat, 93: 247-253, 2005.
53. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E: Differential prognostic impact of hypox-ia induced and diffuse HIF-1 alpha expression in invasive breast cancer. J Clin Pathol, 58: 172-177, 2005.
54. Mehta K, Fok J, Miller FR, Koul D, Sahin AA: Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res, 10: 8068-8076, 2004.
55. Antonyak MA, Miller AM, Jansen JM, Boehm JE, Balkman CE, Wakshlag JJ, Page RL, Cerione RA: Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem, 279: 41461-41467, 2004.
56. Jiang WG, Ablin R, Douglas-Jones A, Mansel RE: Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol Rep, 10: 2039-2044, 2003.
57. Yamaguchi H, Wang HG: Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol Cell Biol, 26: 569-579, 2006.
58. Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE: Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol, 18: 511-518,2005.
59. Resnick MB, Gavilanez M, Newton E, Konkin T, Bhat-tacharya B, Britt DE, Sabo E, Moss SF: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol, 36: 886-892, 2005.
60. Tokes AM, Kulka J, Paku S, Szik A, Paska C, Novak PK, Szilak L, Kiss A, Bogi K, Schaff Z: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res, 7: 296-305, 2005.
61. Martins FC, Teixeira F, Reis I, Geraldes N, Cabrita S, Dias MF: Chemoprevention and mammary neoplastic aggressiveness. Breast J, 14: 608-609, 2008.
62. Stram DO, Wu AH: Beta-carotene and lung cancer: A lesson for future chemoprevention investigations? J Natl Cancer Inst, 95: E4, 2003.
63. Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FL Jr, Omenn GS, Valanis B, Williams JH: The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst, 96: 1743-1750, 2004.
64. Virtamo J, Pietinen P, Huttunen JK, Korhonen P, Malila N, Virtanen MJ, Albanes D, Taylor PR, Albert P: ATBC Study Group. The ATBC Study Group: Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA, 290: 476-485, 2004.
65. Afify A, Zhou H, Howell L, Paulino AF: Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids. Acta Cytol, 49: 621-626, 2005.
66. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL: Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med, 37: 1042-1047, 1996.
67. Ozbudak IH, Karaveli S, Simsek T, Erdogan G, Pestereli E: Neoangiogenesis and expression of hypoxia-inducible factor 1 alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adeno-carcinomas. Gynecol Oncol, 108: 603-608, 2008.
68. Moadel RM, Weldon RH, Katz EB, Lu P, Mani J, Stahl M, Blaufox MD, Pestell RG, Charron MJ, Dadachova E: Positherapy: Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. Cancer Res, 65: 698-702, 2005.
69. Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL: Stunning and its effect on H-FDG uptake and gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med, 47: 603-608, 2006.
70. Grigoriev MY, Suspitsin EN, Togo AV, Pozharisski KM, Ivanova OA, Nardacci R, Falasca L, Piacentini M, Imyanitov EN, Hanson KP: Tissue transglutaminase expression in breast carcinomas. J Exp Clin Cancer Res, 20: 265-268, 2001.
71. Mirshra S., Murphy LJ: Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase II as an insulin-like growth factor-binding protein-3 kinase. J Biol Chemistry, 279: 23863-23868, 2004.
72. Verma A, Mehta K: Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets, 7: 559-565, 2007.
73. Ai L, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan RR, Massoll NA, Brown KD: The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeu-tic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis, 29: 510-518, 2008.
74. Boehm JE, Singh U, Combs C, Antonyak MA, Cerione RA: Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein pi 10 Rb. J Biol Chem, 277: 20127-20130, 2002.
75. Chen JS, Agarwal N, Mehta K: Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat, 71: 237-247, 2002.
76. Vare P, Loikkanen I, Hirvikoski P, Vaarala MH, Soini Y: Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma. Oncol Rep, 19: 25-33, 2008.
77. Higashi Y, Suzuki S, Sakaguchi T, Nakamura T, Baba S, Rei-necker HC, Nakamura S, Konno H: Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. J Surg Res, 139: 68-76, 2007.
78. Hoevel T, Macek R, Swisshelm K, Kubbies M: Reexpression of theTJ protein CLDN1 induces apoptosis in breast tumor spheroids. Int J Cancer, 108: 374-383, 2004.
79. Hoevel T, Macek R, Mundigl O, Swisshelm K, Kubbies M: Expression targeting of the tight junction protein CLDN-1 in CLDN1-negative human breast tumor cells. J Cell Phys-iol, 191: 60-68, 2002.
80. Trosko JE: The role of stem cells and gap junctional intercellular communication in carcinogenesis. J Biochem Mol Biol, 36: 43-48, 2003.
81. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 100: 3983-3988, 2003.
82. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE: Oct-4 expression in adult stem cells: evidence in support of the support of the stem cell theory of carcinogenesis. Carcinogenesis, 26: 495-502, 2005.
83. Webster JD, Yusbasiyan-Gurkan V, Trosko JE, Chang CC, Kiupel M: Expression of the embryonic transcription factor Oct4 in canine neoplasms: a potential marker for stem cell subpopulations in neoplasia. Vet Pathol, 44: 893-900, 2007.
84. Atlasi Y, Mowla ST, Ziaee SA, Bahrami AR: Oct-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer, 120: 1596-1602, 2007.
85. Cerruti PA: Prooxidant states and tumor promotion. Science, 227: 375-347, 1985.
86. Devarajan E, Chen J, Multani AS, Pathak S, Sahin AA, Mehta K: Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol, 20: 913-920, 2002.